NHS England » NHS to roll out long-lasting ‘suit of armour’ jab to protect thousands of premature babies from RSV ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single ...

Nirsevimab Reduced Hospitalizations for Infants With RSV — Monoclonal antibody is highly effective, but in short supply by Katherine Kahn, Staff Writer, MedPage Today December 27, 2023 ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

According to the CDC’s announcement, there is a limited supply of nirsevimab from the manufacturer for the 2023-2024 RSV season, with prefilled syringes of 100-mg doses in especially short supply.

In a logistic regression model, nirsevimab was estimated to be 83% effective in preventing hospitalization from RSV bronchiolitis (95% CI 73.4-89.2) in infants younger than 12 months of age, Naim ...

Thousands of premature babies in the UK can now be protected against a common winter virus which can cause a dangerous lung ...

Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV) prophylaxis, according to a study published online July ...